📰 Jon Patton News
Page 2 - Jon Patton News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jon Patton. Real-time updates on events, politics, business and more.
November 5, 2023
Operator: Good morning, and welcome to Oncolytics Biotechs Third Quarter 2023 Conference Call. All participants are now in listen-only mode.
November 3, 2023
Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreatic Cancer Action Network provides...
November 3, 2023
Novel imaging mass cytometry technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatmentAffirms pelareoreps ability to increase PD-L1 positive cells...
October 23, 2023
7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept SAN DIEGO and...
October 20, 2023
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced that it...
October 16, 2023
Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria SAN DIEGO and CALGARY, AB, Oct. 16, 2023...
September 26, 2023
/PRNewswire/ -- In an effort to continue accelerating new treatment options for people with pancreatic cancer, the Pancreatic Cancer Action Network (PanCAN)...
September 19, 2023
/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced its...
September 7, 2023
/PRNewswire/ -- Oncolytics Biotech® Inc. ("Oncolytics" or the "Company") (NASDAQ: ONCY) (TSX: ONC) today announced that in connection with the previously...
August 14, 2023
Phase 2 data from randomized BRACELET-1 trial in HR+/HER2- metastatic breast cancer showed a near tripling of confirmed ORR, >50% improvement in PFS, and 71%...